Answers are grounded in this paper and cite their sources.
The kynurenine pathway (KP) has been implicated in cytokine-induced depression and anhedonia, a core depression symptom. We examined KP metabolites in relation to depression and anhedonia symptom severity in women with and without HIV (WWH and WWoH). Participants included 239 women (55% WWH, mean age 52 years). Depressive symptoms were measured using the Center for Epidemiologic Studies Depression (CES-D) scale and high depressive symptoms were defined as a score ≥16; anhedonia severity was quantified on two CES-D items. KP metabolites, including quinolinic acid (QA, NMDA receptor agonist) and kynurenic acid (KA, NMDA receptor antagonist), were measured using liquid chromatography-tandem mass spectrometry. Adjusted multivariable linear regression was used to compare metabolites among groups and to assess relationships of KP metabolites with anhedonia and depressive symptoms. A greater proportion of WWH had high depression severity (CES-D ≥16) than WWoH (23% vs. 12%; p=0.03). WWH with CES-D > 16 had greater QA compared to WWH with CES-D<16 (diff = 0.52 SD; p=.02). Using a dimensional quantitative approach, QA levels were positively associated with depressive ( = 0.25; p = .01) and anhedonia symptom severity ( = 0.24; p = .01) among WWH, but not in WWoH. Conversely, KA was inversely associated with anhedonia symptom severity in in WWH ( = -0.20; p =.03 ) and WWoH ( = -0.23; p = .02). This study extends understanding of the role of the KP in depression and anhedonia to WWH and suggests neuroactive metabolites as a possible underlying mechanism. The KP may affect reward neuro-circuitry through increased QA neurotoxicity and decreased KA neuroprotection.
No takes yet. Share an insight, caveat, or question.
Gabbay et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: